Advertisement
Advertisement
U.S. markets close in 4 hours 9 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Surface Oncology, Inc. (SURF)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Visitors trend2W10W9M
1.07000.0000 (0.00%)
As of 04:00PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close1.0700
Open1.0600
Bid0.0000 x 1400
Ask0.0000 x 1100
Day's Range1.0100 - 1.0900
52 Week Range0.5550 - 1.4300
Volume1,462,284
Avg. Volume401,619
Market Cap65.082M
Beta (5Y Monthly)1.75
PE Ratio (TTM)N/A
EPS (TTM)-1.5600
Earnings DateOct 31, 2023 - Nov 06, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for SURF

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Surface Oncology, Inc.
    Analyst Report: Merck & Co IncMerck & Co. is a worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an animal health division. MRK shares are included in the S&P 500.
    Rating
    Fair Value
    Economic Moat
    26 days agoArgus Research
View more
  • GlobeNewswire

    Surface Oncology Announces ISS and Glass Lewis Both Recommend Stockholders Vote “FOR” the Proposed Merger with Coherus BioSciences

    Urges Stockholders to Vote Promptly to Ensure Their Shares are Represented at the September 7th Special MeetingCAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Surface Oncology, Inc. (Nasdaq: SURF) (“Surface”), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that both Institutional Shareholder Services (“ISS”) and Glass, Lewis & Co. (“Glass Lewis”) have recommended Surface stockholders vote “FOR” the a

  • GlobeNewswire

    Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2023

    CAMBRIDGE, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the second quarter 2023. “We are pleased with the progress we have made over the past several months which includes the advancement of the SRF388 and SRF114 clinical trials and the significant efforts we have undertaken towards c

  • Benzinga

    Coherus BioSciences Acquires Small Immuno-Oncology Player Surface Oncology For $40M

    Coherus BioSciences Inc (NASDAQ: CHRS) has agreed to acquire Surface Oncology Inc (NASDAQ: SURF), a clinical-stage immuno-oncology (I-O) company developing next-generation immunotherapies that target the tumor microenvironment. The Surface acquisition adds two clinical stage assets to Coherus' I-O pipeline: SRF388, currently in Phase 2 trials in lung and liver cancer, and SFR114, currently in a Phase 1/2 study as a monotherapy for advanced solid tumors. Coherus will issue shares at $5.2831 per s

Advertisement
Advertisement